Table 2.
Immune-related adverse events reported in the study population.
| Grade 1-2 | Grade 3-4 | |
|---|---|---|
| Any event | 80 (62.02%) | 12 (9.38%) |
| Led to discontinuation of treatment | 0 (0.00%) | 7 (58.34%) |
| Adrenal insufficiency | 12 (15.00%) | 0 (0.00%) |
| Amylase increase | 4 (5.00%) | 1 (8.33%) |
| Arthritis | 4 (5.00%) | 0 (0.00%) |
| Asthenia | 32 (40.00%) | 2 (16.67%) |
| Creatinine increase | 5 (6.25%) | 0 (0.00%) |
| Decreased appetite | 11 (13.75%) | 2 (16.67%) |
| Diarrhea | 11 (13.75%) | 1 (8.33%) |
| Hepatitis | 4 (5.00%) | 0 (0.00%) |
| Hypophysitis | 2 (2.50%) | 0 (0.00%) |
| Lipase increase | 2 (2.50%) | 1 (8.33%) |
| Nausea | 12 (15.00%) | 1 (8.33%) |
| Pancreatitis | 2 (2.50%) | 1 (8.33%) |
| Pneumonitis | 2 (2.50%) | 5 (41.67%) |
| Rash | 7 (8.75%) | 0 (0.00%) |
| Stipsis | 10 (12.50%) | 0 (0.00%) |
| Thyroiditis | 13 (16.25%) | 0 (0.00%) |
| Vomiting | 7 (8.75%) | 0 (0.00%) |
The most frequently reported irAEs of grade 1-2 and grade 3-4 were asthenia (24.81%) and pneumonitis (3.88%), respectively. Seven (5.42%) patients discontinued anti-PD-1/PD-L1 therapy because of irAEs. No treatment-related death was reported.